Seth Bilazarian

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Paul M. Ridker, Jean MacFadyen, Tom Thurén et al. · The Lancet · 2017 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +13

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Paul M. Ridker, Jean MacFadyen, Peter Libby et al. · The Lancet · 2017 · 886 citations · Full text

Veterinary Medicine, Pharmacology, Pharmacotherapy +8

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

Erin A. Bohula, Benjamin M. Scirica, Silvio E. Inzucchi et al. · The Lancet · 2018 · 95 citations · Full text

Medicine, Endocrinology, Pharmacology +14

Signal-averaged electrocardiography in patients with AL (primary) amyloidosis

Simon W Dubrey, Seth Bilazarian, Michael P. LaValley et al. · American Heart Journal · 1997 · 67 citations · Full text

Medicine, Cardiology, Internal Medicine +12

A Case of Lipid Core Plaque Progression and Rupture at the Edge of a Coronary Stent

Sergio Waxman, Mark Freilich, Melissa J. Suter et al. · Circulation Cardiovascular Interventions · 2010 · 40 citations · Full text

Medicine, Biomedical Engineering, Cardiology +17